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Objectives This study sought to assess the impact of intravascular ultrasound (IVUS)-guided versus
angiography-guided drug-eluting stent (DES) implantation.
Background There are limited data on IVUS guidance in the DES era. Therefore, we investigated the
impact of IVUS guidance on clinical outcomes in the MATRIX (Comprehensive Assessment of Sirolimus-
Eluting Stents in Complex Lesions) registry.
Methods The MATRIX registry prospectively enrolled consecutive, unselected patients treated with siroli-
mus-eluting stents (SES) (n  1,504); 631 patients (42%) underwent IVUS-guided stenting, and 873 (58%)
had only angiographic guidance. We assessed 30-day, 1-year, and 2-year rates of death/myocardial infarc-
tion (MI), major adverse cardiac events (cardiac death, MI, or target vessel revascularization), and deﬁnite/
probable stent thrombosis in 548 propensity-score matched patient pairs.
Results After matching, baseline and angiographic characteristics were similar in IVUS and no-IVUS
groups. Patients in the IVUS group had signiﬁcantly less death/MI at 30 days (1.5% vs. 4.6%, p 
0.01), 1 year (3.3% vs. 6.5%, p  0.01), and 2 years (5.0% vs. 8.8%, p  0.01). Patients in the IVUS
group had signiﬁcantly less major adverse cardiac events at 30 days (2.2% vs. 4.8%, p  0.04) and
numerically less major adverse cardiac events at 1 year (9.1% vs. 13.5%, p  0.07) and 2 years
(12.9% vs. 16.7%, p  0.18). Rates of MI were signiﬁcantly lower in the IVUS group at 30 days (1.5%
vs. 4.0%, p  0.01), 1 year (1.8% vs. 4.8%, p  0.01), and 2 years (2.1% vs. 5.7%, p  0.01).
Conclusions IVUS-guided stent implantation appears to be associated with a reduction in both
early and long-term clinical events. Further investigation in randomized controlled trials is
warranted. (J Am Coll Cardiol Intv 2011;4:974–81) © 2011 by the American College of Cardiology
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975Intravascular ultrasound (IVUS) is useful during stent implan-
tation to assess lesion severity, length, and morphology before
stent implantation; to optimize stent expansion, extension, and
apposition; and to identify and treat possible complications
after stent implantation (1). Most of the evidence from the era
of bare-metal stents indicates that IVUS guidance offers
incremental information leading to lower rates of angiographic
restenosis and repeat revascularization (2). In the current era of
drug-eluting stents (DES) with ensuing low restenosis rates,
the relationship between IVUS-guided DES implantation and
clinical outcomes is less well established. Therefore, we inves-
tigated the impact of IVUS guidance on clinical outcomes after
sirolimus-eluting stent (SES) implantation in an unselected
population of patients with obstructive coronary artery disease
from the large MATRIX (Comprehensive Assessment of
Sirolimus-Eluting Stents in Complex Lesions) registry (3).
ethods
The study design has been previously described (3). Briefly,
the MATRIX registry was conducted under an investigative
device exemption approved by the U.S. Food and Drug
Administration. MATRIX was a prospective, open-label,
nonrandomized registry of 1,504 consecutive patients un-
dergoing percutaneous coronary intervention (PCI) with
placement of at least 1 SES for single- or multivessel
coronary artery disease. Inclusion criteria included de novo
or restenotic (including in-stent restenosis and coronary
brachytherapy failure) lesions needing stenting with cumu-
lative length 108 mm and arterial reference diameter 2.5
o 3.5 mm. Exclusion criteria included known allergies to
spirin, clopidogrel or ticlopidine, heparin, bivalirudin, or
ny component of a SES. After appropriate institutional
eview board approval, between March 2004 and August
006, consecutive consented patients who underwent PCI
t the clinical sites using SES were enrolled in this study; all
atients granted written informed consent.
PCI and stent implantation were performed in the
tandard manner. Heparin was administered to maintain an
ctivated clotting time 250 s, although bivalirudin was
sed as the procedural anticoagulant in most cases (85%) per
tandard clinical practice at the 2 clinical sites (Columbia
niversity Medical Center, New York, New York, and
enox Hill Medical Center, New York, New York). Fol-
owing the intracoronary injection of nitroglycerin, pre- and
ost-procedural angiography of the involved vessel(s) was
erformed in at least 2 orthogonal views showing the target
esion with the least amount of foreshortening or vessel
investigator sponsored by Abbott, Medtronic, and Volcano; and whose spouse is on the
advisory board for Abbott. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.t
Manuscript received January 25, 2011; revised manuscript received June 1, 2011,
accepted July 7, 2011.overlap to allow for accurate quantitative coronary angiog-
raphy measurements. Pre- and post-dilation was performed
at the operator’s discretion. In the event of an additional
stent requirement, additional SES use was mandated by the
protocol. Use of glycoprotein IIb/IIIa inhibitors were left to
the discretion of the operator. Successful stent implantation
was defined as a final diameter stenosis of 50% by
quantitative coronary angiography with normal flow. Per
protocol, physicians prescribed aspirin 325 mg daily for 1
month and 81 mg daily thereafter plus clopidogrel 75 mg
daily for at least 1 year after the procedure.
IVUS imaging. IVUS was performed routinely at both par-
ticipating centers and was performed pre-intervention, post-
intervention, or both pre- and post-intervention at the
discretion of the operator with use of dedicated imaging
personnel for setup and acquisition of high-quality images.
Automated pullback was used routinely. The reasons for
IVUS use included restenotic lesion, interrogation of inter-
mediate lesion, imaging of dubious angiographic findings,
stent expansion assessment, and final result verification.
Commercially available IVUS
catheters used in this study in-
cluded Atlantis S (40 MHz,
Boston Scientific, Natick, Mas-
sachusetts) or Eagle Eye (20
MHz, Volcano, Rancho Cor-
dova, California) interfaced with
their respective machine con-
soles. All IVUS studies were
performed after intracoronary
administration of 100 to 200 g
itroglycerin. The IVUS catheter
as advanced 5 mm distal to
he lesion, and imaging was per-
ormed using an automated pullback device to the proximal
eference at a pullback speed of 0.5 mm/s. Routine measure-
ents were recorded pre- and post-stent implantation. The
reatment response to IVUS findings was at the discretion of
he interventional cardiologist.
Follow-up and study endpoints. Follow-up was available in
9.1%, 95.5%, and 85.3% of patients at 30 days, 1 year, and
years, respectively; an independent clinical events com-
ittee (3) adjudicated all clinical endpoints. The primary
ndpoint for the current analysis was the occurrence of the
omposite endpoint of death/MI at 2-year follow-up. Sec-
ndary clinical endpoints included major adverse cardiac
vents (MACE) (a composite of cardiac death, MI or
linically driven target vessel revascularization), death (car-
iac death and noncardiac death), MI (Q-wave MI and
on–Q-wave MI), clinically driven target vessel revascular-
zation, and stent thrombosis. Stent thrombosis was cate-
orized according to the definitions proposed by the Aca-
emic Research Consortium as definite or probable stent
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)hrombosis (4).
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976Statistical analysis. Continuous variables were summarized
sing mean  SD values and compared using the Student t
est or Wilcoxon rank-sum test. Categorical variables were
ummarized using percentages and compared using the
hi-square test. The propensity score was estimated from a
onparsimonious logistic regression model for treatment
ith IVUS versus no IVUS. To calculate the propensity
core, the following variables were entered into the model:
ge, prior coronary artery bypass graft surgery, prior PCI,
iabetes mellitus, number of diseased vessels, number of
reated vessels, number of treated lesions, location of treated
esions (bypass graft, left main, left anterior descending,
ircumflex, right coronary artery), and indication for index
rocedure (elective or acute coronary syndrome). Odds
atios for covariates in this model are shown in Online Table 1.
atients receiving IVUS were then 1-to-1 matched to the
atients receiving no IVUS on propensity score using the
earest available pair matching method. Continuous vari-
bles were summarized using mean  SD and were com-
ared using the paired t test or Wilcoxon signed-ranks test
djusting for the matched pair. Categorical variables were
ummarized using frequencies and percentages and compared
ith Cochran-Mantel-Haenszel test adjusting for the matched
air. Clinical event rates at 30-day and 2-year follow-up were
stimated using the Kaplan-Meier method, and differences
Table 1. Baseline Characteristics
Overall MATRIX
IVUS (n  631) No IVUS (
Age, yrs 64.3 11.1 65.2
Body mass index, kg/m2 29.0 5.7 29.0
Male 74.3% 74.
Diabetes mellitus 30.1% 36.
Hypertension 81.2% 83.
Hyperlipidemia 84.5% 84.
Family history of coronary artery disease 42.2% 40.
Current smoker 11.1% 10.
Chronic renal insufﬁciency 8.5% 11.
Congestive heart failure 7.9% 10.
History of CVA/TIA 6.8% 8.
History of myocardial infarction 29.9% 36.
Percutaneous coronary intervention 47.8% 41.
Coronary artery bypass grafting 14.2% 25.
Coronary brachytherapy 2.3% 1.
Peripheral vascular disease 6.3% 7.
Indication for index procedure
Stable angina with abnormal stress test 65.9% 61.
Unstable angina 30.9% 34.
Acute myocardial infarction 3.1% 3.
Moderate/severe left ventricular dysfunction 7.4% 8.
Values are mean SD or %.CVA cerebrovascular accident; IVUS intravascular ultrasound; MATRIX Comprehensive Assessmeetween groups were compared using the log-rank test. A
alue of p  0.05 indicates statistical significance.
A number of sensitivity analyses were performed to
nvestigate the robustness of the results yielded by the
ropensity-score matched-pair method. First, stepwise mul-
ivariate Cox proportional hazards models were constructed
or 30-day and 2-year clinical outcomes in the overall study
ohort and the propensity-matched cohort with use of
VUS during the procedure forced into every model to
valuate the consistency of the data across all ischemic
vents. Entry and exit criteria were set at p  0.10 for other
andidate variables. The following variables were considered
n the models: age (years), male sex, prior MI, prior
oronary artery bypass grafting, prior PCI, prior brachyther-
py, prior cerebrovascular accident or transient ischemic
ttack, congestive heart failure, history of peripheral vascular
isease, hypertension, hyperlipidemia, diabetes mellitus,
moking, family history of coronary artery disease, chronic
enal insufficiency, acute MI (48 h), cardiogenic shock,
nd multivessel stenting. Moreover, additional Cox models
ere constructed in the overall study cohort with use of
VUS during the procedure and the propensity score as the
nly variables (analysis of covariates), forced into every
odel as proposed by Rosenbaum and Rubin (5) in their
riginal article on the propensity score.
rt Propensity-Matched Cohort
73) p Value IVUS (n  548) No IVUS (n  548) p Value
0.11 64.8 10.9 64.4 11.4 0.53
0.91 29.0 5.7 29.0 5.6 0.89
0.90 73.7% 73.9% 1.00
0.01 31.6% 31.0% 0.90
0.27 81.5% 80.7% 0.76
0.88 83.9% 82.1% 0.47
0.48 40.6% 40.8% 0.95
0.87 10.8% 11.5% 0.70
0.10 8.8% 10.1% 0.54
0.07 8.5% 9.0% 0.83
0.17 7.1% 7.6% 0.73
0.02 29.7% 34.0% 0.13
0.02 43.6% 42.2% 0.67
0.01 15.7% 16.1% 0.93
0.71 2.2% 1.7% 0.66
0.26 6.5% 7.9% 0.41
0.68 66.6% 64.0% 0.79
0.12 30.5% 32.7% 0.47
0.77 2.9% 3.3% 0.86
0.26 6.0% 7.8% 0.56Coho
n  8
11.1
5.5
7%
2%
4%
8%
3%
8%
1%
7%
8%
6%
3%
6%
9%
9%
8%
7%
5%
8%nt of Sirolimus-Eluting Stents in Complex Lesions; TIA transient ischemic attack.
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977Results
A total of 1,504 patients were enrolled in MATRIX; IVUS
was performed during the index procedure in 42.0% of
patients (n  631). There was considerable imbalance in
baseline clinical and angiographic characteristics between
patients in the IVUS group versus the no-IVUS group,
including the rates of diabetes and previous revasculariza-
tion by PCI or surgery (Tables 1 and 2). After propensity
matching, 548 of 631 patients (87%) in the IVUS group were
successfully matched to an equal number of controls. The
propensity-score model discriminated well (C-statistic: 0.67).
The 2 matched groups had similar clinical and angiographic
characteristics (Tables 1 and 2). In the IVUS group, lesion
re-dilation was less often used (54.0% vs. 70.2%, p  0.01),
ost-dilation was performed more often (42.5% vs. 34.1%, p
.01), the maximum stent inflation pressure was somewhat
igher (15.5 2.6 atm vs. 15.3 2.6 atm, p  0.04), and the
nal stent diameter was slightly larger than in the no-IVUS
roup (3.1 0.4 mm vs. 3.0 0.4 mm, p  0.01).
Clinical outcome. Clinical event rates are presented in Table 3.
n the entire MATRIX population, the 30-day rate of
Table 2. Angiographic and Procedural Characteristics
Overall MATRIX
IVUS (n  631) No IVUS (n
Number of lesions treated 1,260 1,61
Number of lesions treated per patient 1.9 1.0 1.8
Number of vessels treated per patient 1.4 0.6 1.3
Treated vessel
Left main coronary artery 4.8% 2.3
Left anterior descending coronary artery 55.3% 36.8
Left circumﬂex coronary artery 35.8% 35.2
Ramus intermedius 5.7% 3.4
Right coronary artery 26.1% 36.2
Saphenous vein graft 1.7% 7.0
Arterial bypass graft 0.2% 0.9
Lesion location
Ostial 8.7% 6.7
Proximal 31.0% 30.3
Mid 36.4% 32.3
Distal 12.9% 17.3
Lesion length, mm 17.3 9.6 18.5
AHA/ACC lesion type B2/C 68.2% 65.5
Rotational atherectomy 1.0% 0.8
Stent length, mm 23.5 12.24 24.5
Stent diameter, mm 3.09 0.41 3.00
Maximum inﬂation pressure, atm 15.4 4.7 14.6
Pre-dilation performed 54.5% 71.2
Post-dilation performed 43.8% 33.6
Glycoprotein IIb/IIIa inhibitor used 8.9% 7.7
Values are mean SD or %.ACC American College of Cardiology; AHA American Heart Association; other abbreviations as in Taeath/MI was significantly lower in the IVUS group with
umerically lower mortality (p  0.056). At 1 year, patients
n the IVUS group had significantly less death/MI, MACE,
nd MI. At 2 years, patients in the IVUS group had
ignificantly lower rates of death/MI and MI and numeri-
ally lower MACE (p  0.053).
In the propensity-matched cohort, at 30 days, patients in the
VUS group had significantly lower rates of death/MI,
ACE, mortality, and MI than did the patients in the
o-IVUS group. At 1-year follow-up, the significant reduction
n mortality with IVUS was no longer present; however, rates
f death/MI, MACE, and MI were still significantly lower in
he IVUS group. At 2-year follow-up, there was a signif-
cant reduction in death/MI and MI and numerically
ower MACE in the IVUS group (p  0.06). Although
ates of clinically driven TVR and definite/probable stent
hrombosis were numerically lower in the IVUS group
hroughout the 2-year follow-up period, there was no
ignificant difference. Figure 1 shows Kaplan-Meier
urves for all clinical endpoints up to 2-year follow-up in
he propensity-matched cohort.
Propensity-Matched Cohort
3) p Value IVUS (n  548) No IVUS (n  548) p Value
1,091 1,070
0.12 1.9 1.0 1.9 1.0 0.71
0.01 1.3 0.6 1.3 0.6 0.91
0.01 0.96
3.3% 3.3%
51.1% 50.9%
37.8% 38.3%
5.5% 4.0%
28.5% 28.3%
1.6% 1.6%
0.2% 0.4%
0.01 0.43
8.3% 7.3%
31.9% 31.6%
35.8% 32.7%
13.4% 15.0%
0.01 17.5 9.6 17.9 9.3 0.33
0.17 67.0% 62.8% 0.25
0.42 1.2% 0.9% 0.52
0.05 23.3 12.0 23.8 12.2 0.38
0.01 3.1 0.4 3.0 0.4 0.01
0.01 15.5 2.6 15.3 2.6 0.04
0.01 54.0% 70.2% 0.01
0.01 42.5% 34.1% 0.01
0.45 8.2% 8.4% 0.91Cohort
 87
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978Figure 2 shows consistent adjusted hazard ratios for the use of
VUS imaging in association with all 30-day and 2-year clinical
utcomes for multivariate Cox regression models in the entire
ATRIX cohort and the propensity-matched cohort. IVUS
maging was a statistically significant predictor of early (30-day)
vents including death/MI in the entire MATRIX cohort and
lso of death/MI and MACE in the propensity-matched cohort.
dditionally, IVUS-guidance was identified as a statistically sig-
ificant predictor of death/MI and MI at 2 years in both the entire
ATRIX cohort and the propensity-matched cohorts. Addi-
ional Cox models in the entire MATRIX cohort into which we
orced only use of IVUS imaging and the propensity score as
ovariates (analysis of covariates) yielded qualitatively similar haz-
Table 3. Clinical Outcome in the Entire MATRIX Pop
Overall MATRIX Coho
IVUS (n  631) No IVUS (n  8
30-day outcome
Death/MI 1.6% 3.6%
MACE 2.5% 3.8%
Mortality 0.0% 0.6%
Cardiac death 0.0% 0.3%
Noncardiac death 0.0% 0.3%
MI 1.6% 3.1%
Q-wave 0.2% 0.2%
Non–Q-wave 1.4% 2.9%
Clinically driven TVR 1.0% 1.2%
Deﬁnite/probable ST 0.2% 0.5%
1-yr outcome
Death/MI 3.6% 5.8%
MACE 9.6% 13.0%
Mortality 1.8% 2.1%
Cardiac death 1.0% 0.8%
Noncardiac death 0.8% 1.3%
MI 1.9% 4.1%
Q-wave 0.2% 0.6%
Non–Q-wave 1.8% 3.5%
Clinically driven TVR 7.3% 9.9%
Deﬁnite/probable ST 0.3% 0.9%
2-yr outcome
Death/MI 5.0% 9.1%
MACE 13.4% 17.0%
Mortality 3.0% 4.5%
Cardiac death 1.2% 1.9%
Noncardiac death 1.9% 1.6%
MI 2.1% 5.1%
Q-wave 0.2% 0.6%
Non–Q-wave 2.0% 4.6%
Clinically driven TVR 11.1% 12.8%
Deﬁnite/probable ST 0.5% 0.9%
MACEmajor adverse cardiac events; MImyocardial infarction; ST
as in Table 1.rd ratios (results shown in Online Table 2).Discussion
Notwithstanding the low overall event rates after SES implanta-
tion in this “real world” patient population, the main finding from
the current study with blinded evaluation of endpoints was that
IVUS guidance was associated with a reduction in early (30-day),
medium-term (1-year), and long-term (2-year) clinical outcomes,
mostly driven by a reduction in the incidence of MI and the
composite endpoint of death or MI.
Due to its ability to provide additional information on lesion
characteristics (pre-intervention) and stent deployment (post-
intervention), IVUS imaging plays an important role in opti-
mizing DES placement (6). However, only a modest number
and the Propensity-Matched Cohort
Propensity-Matched Cohort
p Value IVUS (n  548) No IVUS (n  548) p Value
0.02 1.5% 4.6% 0.01
0.18 2.2% 4.8% 0.04
0.056 0.0% 0.7% 0.99
0.14 0.0% 0.6% 0.99
0.14 0.0% 0.2% 0.99
0.06 1.5% 4.0% 0.01
0.76 0.2% 0.2% 1.0
0.06 1.3% 3.9% 0.01
0.71 0.7% 1.1% 0.53
0.32 0.2% 0.4% 0.57
0.04 3.3% 6.5% 0.01
0.04 9.1% 13.5% 0.07
0.64 1.7% 2.1% 0.49
0.77 0.7% 0.9% 0.74
0.23 1.0% 1.1% 0.85
0.02 1.8% 4.8% 0.01
0.21 0.2% 0.6% 0.34
0.05 1.7% 4.2% 0.01
0.09 7.3% 9.3% 0.43
0.15 0.4% 0.7% 0.42
0.01 5.0% 8.8% 0.01
0.053 12.9% 16.7% 0.18
0.18 3.1% 3.8% 0.39
0.63 1.0% 1.8% 0.28
0.32 2.2% 2.0% 0.62
0.01 2.1% 5.7% 0.01
0.21 0.2% 0.6% 0.34
0.01 1.9% 5.1% 0.01
0.25 11.0% 12.1% 0.70
0.16 0.6% 1.0% 0.48
hrombosis; TVR target vessel revascularization; other abbreviationsulation
rt
73)
stent tof studies have been published investigating the impact of
; MI 
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979IVUS-guided compared with angiography-guided DES im-
plantation. A study by Roy et al. (7) compared 1-year clinical
outcomes in 884 patients who underwent IVUS-guided PCI
with a propensity-matched cohort of angiographically guided
patients. IVUS guidance was found to be associated with lower
rates of definite stent thrombosis at 30 days (0.5% vs. 1.4%,
p  0.05) and 1 year (0.7% vs. 2.0%, p  0.01) with a trend
toward lower target lesion revascularization at 12 months
Figure 1. Kaplan-Meier Curves of Clinical Outcomes to 2-Year Follow-Up in
IVUS  intravascular ultrasound; MACE  major adverse cardiovascular events(5.1% vs. 7.2%, p  0.07). These investigators did not find asignificant difference in MI between patients treated with
IVUS guidance and those without. This difference can possibly
be explained by the fact that only Q-wave MI was collected by
Roy et al. (7), whereas both Q-wave and non–Q-wave MIs
were collected in the present study. Park et al. (8) reported a
significant reduction in 3-year mortality with IVUS guidance
in a propensity-matched cohort of 145 matched patient pairs
who underwent DES implantation for unprotected left main
ropensity-Matched Cohort
myocardial infarction; TVR  target vessel revascularization.the Pcoronary artery lesions. A recent study by Kim et al. (9)
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980reported that IVUS guidance significantly reduced 4-year
mortality and very late stent thrombosis after propensity-score
adjustment in 420 patients receiving DES for bifurcation
lesions. The studies by Roy et al. (7), Park et al. (8), and the
urrent investigators were performed at institutions that rou-
inely, systematically, and similarly use IVUS during stent
mplantation. Additional information provided by IVUS that,
nlike angiography, allows a tomographic image of coronary
rtery lesions (pre-procedure) and implanted stents (post-
rocedure), likely influenced the treatment approach as illus-
rated by the increased usage of post-dilation and direct
tenting in the IVUS cohort, especially in the current study.
In the present study, multiple statistical approaches were
sed to evaluate the impact of IVUS guidance on clinical
utcomes (propensity-matching, multivariate Cox methods,
nd covariate adjustment with the propensity score), yielding
imilar results (Table 3, Online Table 2, Fig. 2). The analyses
uggested IVUS-guided SES implantation was associated with
reduction in both early (30-days) and long-term (up to 2
ears) events, most notably a reduction in MI.
Clinical event rates in the IVUS and no-IVUS groups
tarted to diverge soon after the procedure; at 30 days, there
ere significant differences in death/MI, MACE, mortality,
Figure 2. Adjusted Hazard Ratios for IVUS Use for 30-Day and 2-Year Clinic
Adjusted hazard ratios (HR) (multivariate analysis by Cox methods) for IVUS us
Assessment of Sirolimus-Eluting Stents in Complex Lesions) cohort and the pro
both statistical approaches, and indicate a favorable effect of IVUS use. CI  cnd MI in favor of the IVUS group. Optimization of stent (lacement in terms of adequate lesion coverage and minimal
resence of residual reference segment disease, adequate stent
xpansion and apposition, and detection of dissections and
ther complications could explain these favorable short-term
esults. Visual evaluation of the Kaplan-Meier event curves
uggests that clinical events occurred with similar frequency
fter the early (30-day) separation of events similar to the stent
hrombosis free curves reported by Roy et al. (7). Early events
ere, presumably, mostly related to mechanical issues and were
educed by use of IVUS, whereas later events were more likely
elated to natural progression of atherosclerotic disease or
iologic effects of the DES, but not to mechanical issues and,
herefore, were not affected by IVUS guidance.
Due to the low incidence of the important and frequently
atastrophic adverse event of stent thrombosis, our study was
nderpowered to detect any differences in stent thrombosis
ates with IVUS guidance. Definite/probable stent thrombosis
as numerically lower in the IVUS group throughout the
-year follow-up period, but there were no statistically signif-
cant differences as in the study by Roy et al. (7). Procedural
echanical factors such as inadequate stent expansion and residual
dge problems or geographic miss are important correlates of stent
hrombosis that can be identified and corrected with IVUS
tcome in the MATRIX and Propensity-Matched Cohorts
0-day and 2-year clinical outcome in the entire MATRIX (Comprehensive
ty-matched cohort. HRs are consistent (qualitatively unidirectional) across
nce interval; other abbreviations as in Figure 1.al Ou
e for 3
pensi10,11). Moreover, a recent study suggested optimal stent sizing
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981with IVUS might contribute to complete neointimal coverage
(that is thought to contribute to very late stent thrombosis) after
SES implantation (12). Finally, IVUS guidance can be useful in
understanding the mechanisms of restenosis (13).
The current study adds to the evidence supporting IVUS
guidance in DES placement, although no randomized trials
have been completed to date to confirm these findings.
Therefore, a large, adequately powered randomized trial
investigating the impact of IVUS versus angiography-
guided PCI with DES seems warranted.
Study limitations. This was a nonrandomized, observational
study performed in 2 centers where IVUS guidance is used in
a significant proportion of everyday practice. We used propen-
sity matching to reduce potential bias in patient selection.
Although clinical and angiographic characteristics were well
balanced in matched patients, the possibility remains of un-
known confounders that were not accounted for in the
propensity-matching process. For example, we were unable to
adjust for the operator performing the procedure, as this
variable was not collected in the study database. Some of the
analyses were based on a small number of endpoint events;
however, results were directionally similar in the propensity-
matched comparison as well as in multivariate models with few
variables (only IVUS performed a propensity score) and mod-
els using more covariates. Although the U.S. Food and Drug
Administration–approved SES was the only stent used in this
registry, there is no strong rationale for why the impact of
IVUS on clinical outcomes ought to differ for other DES. In
our clinical practice, the decision to use IVUS imaging was
independent of the type of stent. This is especially true because
the separation in curves is all in the first 30 days, implying
mechanical rather than drug-related effects. Finally, quantita-
tive IVUS assessment was not performed; therefore, we could
not assess the relationship between quantitative imaging pa-
rameters and clinical outcomes.
Conclusions
IVUS-guided stent implantation appears to be associated with
a reduction in both early and long-term clinical events. These
findings may be considered hypothesis-generating and further
investigation in randomized controlled trials is warranted.
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APPENDIX
For the odds ratios for covariates in the propensity score logistic regres-
sion model and for independent predictors of clinical outcome according to
3 different methods, please see the online version of this paper.
